Covid 19: We need well-designed clinical trials

On June 23, Patanjali Ayurved claimed that its preparations, ‘Coronil’ would cure COVID-19 in just a week.  Scientists, researchers, physicians and media registered their strong protest and expressed robust disbelief for the outrageous and misleading ads.  The company claimed that their medicine was tested in a randomised controlled trial (RCT) among COVID-19 positive patients and … Read the essay

The many questions about Favipiravir

The Drugs Controller General of India (DCGI) has approved Glenmark Pharmaceuticals, an Indian pharmaceutical company, to sell generic versions of Favipiravir for the treatment of COVID-19. This drug, originally invented by a Japanese company, was meant to treat influenza. After the outbreak of COVID-19, doctors in China and Russia started using it to treat COVID-19 … Read the essay

Clinical Research during Covid Era

On 18 June 2020, Dr. C. S. Pramesh, the Director of the Tata Memorial Hospital texted me a message and then called me asking if I would be willing to do a talk on Covid and research during Pandemic. A day after. Although I had little time to prepare, I didn’t blink an eyelid to … Read the essay

Primum Non Nocere

No other drug, at least in the early phase of Covid pandemic, evoked as much interest, publicity, blind and demand as Hydroxychloroquine did. It took a couple of well -designed randomized controlled trials to indicate that the drug does not work, and is associated with serious adverse events when used to prevent or treat Covid. … Read the essay

Hydroxychloroquine and COVID-19: Can we go back to science?

Hydroxychloroquine (HCQ) has been the biggest buzzword across the world lately. Until December 2019, this was a meek drug, used mainly by rheumatologists, internists, and dermatologists for inflammatory diseases. Its cousin Chloroquine has been the most popular drug for malaria. We have known and used these drugs for decades. The antiviral properties of these drugs … Read the essay